Bupivacaine extended release - Pacira Pharmaceuticals

Drug Profile

Bupivacaine extended release - Pacira Pharmaceuticals

Alternative Names: Bupivacaine extended-release - Pacira Pharmaceuticals; Bupivacaine extended-release liposome injection; Bupivacaine liposome extended-release injectable suspension; Bupivacaine liposome injectable suspension; DepoBupivacaine; Exparel; SKY-0402

Latest Information Update: 16 May 2017

Price : $50

At a glance

  • Originator SkyePharma Inc
  • Developer Pacira Pharmaceuticals
  • Class Anilides; Local anaesthetics; Non-opioid analgesics; Pipecolic acids; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Postoperative pain
  • Preregistration Anaesthesia
  • Phase III Dental pain
  • Phase I Pain
  • No development reported Musculoskeletal pain

Most Recent Events

  • 04 May 2017 Pacira Pharmaceuticals has patent protection for bupivacaine extended release in USA
  • 25 Jan 2017 Pacira Pharmaceuticals and DePuy Synthes agree to co-promote bupivacaine extended-release in USA for Postoperative pain
  • 02 Dec 2016 Pacira Pharmaceuticals plans a phase I trial for Postoperative pain in USA (Infiltration) (NCT02985762)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top